Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

NCT01178216 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

End Stage Renal Disease

Interventions

BIOLOGICAL: Rituxan

Sponsor

Stanley Jordan, MD

Collaborators

[object Object]